Aileron Therapeutics Stock Piotroski F Score
| ALRN Stock | USD 3.23 0.05 1.57% |
Aileron | Piotroski F Score |
At this time, it appears that Aileron Therapeutics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Decreasing |
| Asset Turnover Growth | No Change |
| Current Ratio Change | Increase |
| Long Term Debt Over Assets Change | Lower Leverage |
| Change In Outstending Shares | Increase |
| Change in Gross Margin | No Change |
Aileron Therapeutics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Aileron Therapeutics is to make sure Aileron is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Aileron Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Aileron Therapeutics' financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Current Liabilities | 4.5 M | 4.4 M |
|
| |||||
| Total Assets | 125.3 M | 119.3 M |
|
| |||||
| Total Current Assets | 26.4 M | 18.3 M |
|
|
Aileron Therapeutics F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Aileron Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Aileron Therapeutics in a much-optimized way.
| 0.53 | 0.83 | -0.29 | 0.78 | 0.61 | -0.5 | ||
| 0.53 | 0.22 | 0.33 | 0.92 | -0.04 | -0.09 | ||
| 0.83 | 0.22 | -0.58 | 0.45 | 0.49 | -0.72 | ||
| -0.29 | 0.33 | -0.58 | 0.16 | -0.5 | 0.77 | ||
| 0.78 | 0.92 | 0.45 | 0.16 | 0.33 | -0.22 | ||
| 0.61 | -0.04 | 0.49 | -0.5 | 0.33 | -0.42 | ||
| -0.5 | -0.09 | -0.72 | 0.77 | -0.22 | -0.42 |
Click cells to compare fundamentals
About Aileron Therapeutics Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
Aileron Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aileron Therapeutics from analyzing Aileron Therapeutics' financial statements. These drivers represent accounts that assess Aileron Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aileron Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 14.1M | 36.3M | 50.0M | 10.8M | 14.0M | 13.3M | |
| Enterprise Value | 13.8M | 29.6M | 46.6M | 5.6M | 88.1M | 92.6M |
Aileron Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aileron Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aileron Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
About Aileron Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aileron Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aileron Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aileron Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Aileron Stock
When determining whether Aileron Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aileron Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aileron Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aileron Therapeutics Stock:Check out Aileron Therapeutics Altman Z Score, Aileron Therapeutics Correlation, Aileron Therapeutics Valuation, as well as analyze Aileron Therapeutics Alpha and Beta and Aileron Therapeutics Hype Analysis. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.23) | Return On Assets (0.20) | Return On Equity (0.34) |
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.